BPC-157: Research Overview, Study Status, and Quality Criteria

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The body of research on BPC-157 predominantly originates from animal models and cell cultures, i.e., from preclinical research. The sequence is derived from an endogenous gastric juice peptide, originally described from human gastric juice. BPC-157 is not an approved drug but is handled exclusively as research material.

The abbreviation stands for "Body Protection Compound," derived from a larger protein isolated from human gastric juice in the early 1990s (Whitehouse 2025). The synthetically produced peptide is typically available lyophilized (freeze-dried) as research material.

Key technical data at a glance:

Parameter	Specification
Substance Class	Synthetic pentadecapeptide (15 amino acids)
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
CAS Number	137525-51-0
Empirical Formula	C62H98N16O22
Molecular Weight	approx. 1419.55 g/mol
Form	Lyophilized (freeze-dried powder)
Status	Research material, not an approved drug

Important for context: BPC-157 is not approved for medical use by any regulatory authority. A current literature and patent review states that the peptide is "not approved by the FDA and other global regulatory authorities for use in standard medicine" due to the lack of comprehensive human clinical trials (Józwiak et al. 2025). This article is a neutral research overview intended for researchers, not users. It does not contain instructions for use, dosage, or reconstitution.

BPC-157 Research Status: What has been investigated so far

The available evidence on BPC-157 comes almost entirely from preclinical research, i.e., from animal and in vitro models. A 2025 review states that "most, if not all, studies are limited to small animal models (i.e., rats and mice)" and that the routes of administration investigated were also limited (Józwiak et al. 2025). The transferability of these findings to humans has therefore not been proven.

Another characteristic of the data is its concentration: A very large proportion of the published work stems from a single research group led by Predrag Sikiric, whose first description of the peptide appeared in 1993 (Whitehouse 2025; Sikiric et al. 2024). Broad, independent replication by many independent groups has been limited so far. This must be taken into account when evaluating the evidential value.

Model systems in which BPC-157 has been investigated

The following points only name the model systems in which the peptide appeared as an object of investigation in the literature. These are pure model descriptions in the preterite. They are not an indication of benefit and no statement about an effect in humans:

• Gastrointestinal model systems. Early on, BPC-157 was described as a stable peptide in gastric juice and used as an object of investigation in rodent models of the digestive tract. This is a pure model description with no statement on benefit (Whitehouse 2025; Sikiric et al. 2024).
• Connective and muscle tissue models. Part of the preclinical literature assigned the peptide to animal models related to connective and muscle tissue as an object of investigation. No outcome is claimed here; it remains a pure model description (Józwiak et al. 2025).
• Vascular system models. In rodents, the peptide appeared in model systems related to vascular biology as an object of investigation. This is a model description without indication of benefit (Sikiric et al. 2024).
• Central nervous system models. A review summarizes work in which the peptide was investigated in rodent models related to the central nervous system (Vukojević et al. 2021). The findings come exclusively from animal models. They are not an indication of benefit, no statement about an effect in humans, and no statement about a therapeutic effect in a disease.

Methodological classification: Preclinical findings from animal and in vitro models are an early stage of research. They allow for hypotheses but no conclusions about safety or benefit in humans. As long as controlled clinical trials are lacking, BPC-157 remains a pure research material.

What does preclinical evidence mean?

The term preclinical describes research that precedes controlled human studies. This includes in vitro work on cell cultures and in vivo work on experimental animals, in the case of BPC-157 predominantly rats and mice (Józwiak et al. 2025). This stage serves to form biological hypotheses and gather initial observations. It does not replace clinical testing.

Several limitations are relevant for classifying the research status. Firstly, findings from rodents cannot be directly transferred to humans, as metabolism, dose-response relationships, and physiology differ. Secondly, a finding only gains reliability when it is reproduced by several independent research groups. Precisely this broad independent replication has been limited for BPC-157 so far, because a large part of the work comes from a single research group (Whitehouse 2025). Thirdly, the model systems and routes of administration used in the literature are limited, which further restricts the scope of the observations (Józwiak et al. 2025).

For research practice, this means: Preclinical data show what science has investigated, not what applies to humans. For this reason, the correct description of BPC-157 remains that of a research material whose properties are the subject of investigation, and not of a proven application.

Purity and quality criteria for BPC-157 as research material

For reproducible research, the analytical quality of the material is crucial. Even small amounts of synthesis by-products or impurities in a pentadecapeptide like BPC-157 can shift the starting conditions of an experiment. Three analyses form the core of the usual quality assessment: HPLC purity, mass spectrometric identity, and endotoxin status. The first two will be discussed in more detail in the next section.

• HPLC purity. High-performance liquid chromatography separates the target peptide from synthesis by-products and indicates purity as a percentage. A value of at least 98 percent has become the market standard for research peptides, because below this, the proportion of unclear accompanying substances becomes too high for controlled experiments.
• MS identity. Mass spectrometry confirms, via the measured molecular weight, that the specified molecule is actually present and not a shortened or elongated fragment.
• Endotoxin status. The endotoxin content is usually determined by LAL test.

In addition, depending on the material, water content, peptide content, and residual solvents are determined. These values should ideally be included in a batch-specific Certificate of Analysis (COA) that precisely documents the batch being supplied. What should be in a COA and how to interpret the data is explained in detail in the EONA COA Guide.

HPLC and MS in detail: why both methods are necessary

HPLC and MS measure different properties and complement each other. Only together do they prove that a sample is both pure and the correct molecule. A single method alone leaves a gap.

Purity determination in peptide analytics is usually performed by reversed-phase HPLC (RP-HPLC). Here, a non-polar stationary phase separates the components of a sample according to their polarity. The target peptide elutes as a distinct peak, while synthesis by-products such as truncated sequences appear as additional peaks. The purity value is derived from the area proportion of the target peak relative to the total area. RP-HPLC is particularly suitable for peptides because it reliably separates closely related accompanying substances. However, a high HPLC value only indicates that the sample is uniform, not which molecule it is.

Mass spectrometry closes this gap. It measures the mass-to-charge ratio and thus the molecular weight of the existing molecule. If the measured value matches the theoretical mass of approximately 1419.55 g/mol, the identity is confirmed. If the mass deviates, a different molecule is present, such as a fragment shortened by one amino acid, which may lie close to the target peak in HPLC. Only the combination of both methods answers the two central questions together: Is the sample pure and is it the correct molecule?

Endotoxins and peptide content

In addition to purity and identity, two other quantities are relevant for evaluating research material: the endotoxin content and the actual peptide content.

Endotoxins are components of the outer membrane of gram-negative bacteria (lipopolysaccharides). They can enter a sample during synthesis or processing and trigger their own biological reactions in cell and animal models, thereby falsifying results. The Limulus Amoebocyte Lysate test (LAL test) quantifies these endotoxins. The content is usually given in endotoxin units per milligram (EU/mg). The concept is: the lower the value, the lower the risk that endotoxins will interfere with an experiment. What threshold value is appropriate depends on the respective experimental setup.

A frequently overlooked quantity is the net peptide content. The gross mass in a vial does not correspond to the mass of pure peptide. Lyophilized material typically also contains residual water and counterions from synthesis, for example, from the purification process. The peptide content indicates what proportion of the weighed gross mass actually consists of the peptide. For reproducible research, this distinction between net peptide and gross mass is important because otherwise the true amount of the subject of investigation is overestimated or underestimated. A complete COA therefore ideally not only shows HPLC purity and MS identity but also peptide content and endotoxin status.

What to look for when sourcing research material

Since research peptides are not subject to the same regulatory approval processes as medicines, the selection of the source is particularly important. The following checkpoints have proven useful in general:

1. Origin and Transparency. Traceable information on manufacturing and origin is a quality indicator. EONA documents origin and test values batch-specifically.
2. Batch-specific COA. A COA is only meaningful if it refers to the specific batch and not to a generic sample. It should specify the previously described test parameters, i.e., HPLC purity, MS identity, peptide content, and endotoxin status.
3. Independent cross-check. Values gain reliability if they are additionally independently academically cross-checked, if offered by the provider, instead of relying solely on manufacturer's information.
4. Handling and Storage. Lyophilized material should be stored cool, dry, and protected from light. This information relates exclusively to the storage of the research material, not its application.

The technical specification and batch-specific COA for BPC-157 as research material can be found on the BPC-157 product page. Specific purity values only apply to the documented batch, not generally.

Frequently Asked Questions about BPC-157

What exactly is BPC-157?

BPC-157 is a synthetic pentadecapeptide of 15 amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, empirical formula C62H98N16O22). It is derived from an endogenous gastric juice peptide and is handled exclusively as research material. It is not an approved drug.

What is the research status of BPC-157?

The available evidence is almost entirely preclinical and comes from animal and in vitro models, predominantly in rats and mice (Józwiak et al. 2025). A large proportion of the work comes from a single research group. Transferability to humans has not been proven.

Is BPC-157 an approved drug?

No. According to current literature, BPC-157 is not approved by the FDA or other global regulatory authorities for use in standard medicine due to a lack of comprehensive clinical trials (Józwiak et al. 2025). It is not intended for human or animal use.

How do I identify high-quality BPC-157 research material?

By verifiable origin and a batch-specific COA that documents HPLC purity (market standard at least 98 percent), MS identity, and LAL endotoxin status. An independent cross-check increases the reliability of the information.

How is BPC-157 stored as research material?

Lyophilized material is stored cool, dry, and protected from light. This information pertains exclusively to storage and is not a usage instruction.

Related Articles

• What are peptides – Fundamentals and classes of research peptides
• TB-500 and Thymosin Beta-4 – related regeneration research topic
• GHK-Cu Copper Peptide – Research overview of copper tripeptide
• How to read a peptide COA correctly – Understanding certificates of analysis
• Peptide purity and HPLC – how purity is measured
• Proper storage of peptides – Handling lyophilized research material

Sources

1. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide – Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. DOI: 10.3390/ph18020185. mdpi.com/1424-8247/18/2/185
2. Sikiric P, Boban Blagaic A, Strbe S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. DOI: 10.3390/ph17040461. pubmed.ncbi.nlm.nih.gov/38675421
3. Vukojević J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research. 2021;17(3):482-487. DOI: 10.4103/1673-5374.320969. pmc.ncbi.nlm.nih.gov/articles/PMC8504390
4. Whitehouse M. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT). Inflammopharmacology. 2025;33(8):4879-4881. DOI: 10.1007/s10787-025-01882-z. pmc.ncbi.nlm.nih.gov/articles/PMC12396989

Editorial Note

This article was created by the EONA editorial team and last updated in June 2026. It serves as neutral scientific information on BPC-157 as a research material. It does not constitute medical advice or a statement on safety or benefit in humans. BPC-157 is not an approved drug and is not intended for human or animal use. The research findings mentioned originate from preclinical animal and in vitro models.